Navigation Links
Sentinel node biopsy safe, effective in head and neck melanomas, U-M study finds
Date:8/5/2011

This release is available in Spanish.

ANN ARBOR, Mich. A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

Sentinel lymph node biopsy involves injecting a special dye to identify the first node where cancer would likely spread. If that node is clean, patients can avoid further debilitating surgery to remove multiple lymph nodes. If that node shows cancer, patients know they need the more extensive surgery or further treatment with radiation, chemotherapy or a clinical trial. Patients with melanoma of a certain size or larger are routinely offered this procedure.

But many surgeons believed that the complex anatomy combined with the critical nerves and blood vessels in the head and neck area made sentinel lymph node biopsy unsafe and inaccurate for melanomas in that region.

In the current study, which appears online in Cancer, researchers looked at 353 head and neck melanoma patients who had received sentinel lymph node biopsy at U-M over a 10-year period. After reviewing patients' records, the researchers found that the sentinel lymph node could be identified in all but one patient, and no patients sustained permanent nerve injuries during the procedure.

About 20 percent of the patients had at least one sentinel node positive for cancer and were referred for a complete dissection to remove additional lymph nodes.

Among the remaining 283 patients with negative sentinel nodes, 12 patients recurred in the region where the sentinel lymph node was identified. This suggests that the test yielded 12 false-negative results, which means a negative test was incorrect 4 percent of the time. This rate is similar when sentinel lymph node biopsy is us
'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. The sentinel node dilemma in breast cancer surgery
2. Microbubbles to light the way to sentinel lymph nodes of breast cancer patients
3. Sentinel Life Medicare Supplement – Significant Commission Increase Announced
4. MedPage Today(R) and Milwaukee Journal Sentinel Develop Journalism Content Collaboration for Enterprise Medical Reporting
5. For Many, Risks of Lung Biopsy May Outweigh Benefits: Study
6. Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis
7. Shave biopsy is a safe and acceptable method for initial evaluation of melanoma
8. New technology fuses MRI, ultrasound to achieve targeted biopsy of prostate cancer
9. Closely monitoring low-risk prostate cancer, with biopsy, does not raise risk of death
10. Elastography helps identify patients who need biopsy
11. Virtual biopsy may allow earlier diagnosis of brain disorder in athletes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sentinel node biopsy safe, effective in head and neck melanomas, U-M study finds 
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... services to help patients in need. Most people know that general health emergencies, such ... Unfortunately, a fewer amount of people know where to turn to during a dental ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
(Date:8/3/2015)... NJ (PRWEB) , ... August 03, 2015 , ... ... to announce the development of it’s new program “Designing Secure Healthcare Systems” ... architects, engineers and technology leaders from healthcare organizations with access to the tactics, ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... YORK, April 28 Crystal Research Associates, LLC,announced ... Overview(R),(EIO(R)) on BioCurex Inc. (OTC Bulletin Board: BOCX). ... http://www.crystalra.com ., BioCurex, Inc. ("BioCurex" or "the ... diagnosis, imaging, and therapy that target,a global oncology ...
... Establishes Effects of Puzzle ... and Word Games on the Human Body and Mind, ... Carolina,University,s Department of Recreation and Leisure Studies today revealed,the ... measured,the stress-relieving and other mood-lifting effects of so-called "casual",video ...
... drug developed to relieve one of the major side ... approval from the United States Food and Drug Administration ... of opioid-induced bowel disorders in patients receiving palliative care ... FDA,s European equivalent, the Committee for Medicinal Products for ...
... Sylvie Bouchard to Retire from Company -, ... (TSX: DDS;,NASDAQ: DDSS) today announced that Claire Brulle, ... Officer of the Company. Incumbent,Chief Medical Officer Dr. ... on her career practicing medicine., "Dr. Brulle ...
... Available at 1,440 Stores in May 2008, ... Ltd., a medical,device company publicly traded on the ... its RESPeRATE(R) hypertension treatment device,clinically-proven to significantly lower ... the United Kingdom this May through,Lloyds Pharmacy, the ...
... TORONTO, April 28 Readers in Europe and other ... Story, the debut book,from London-born author Shireen Jeejeebhoy. It ... who made medical history as the first,person to live ... The book has just scooped awards in the US ...
Cached Medicine News:Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc. 2Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc. 3Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 2Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 3Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 4Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 5Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 6Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 7Health News:Drug developed at the University of Chicago wins FDA approval 2Health News:Drug developed at the University of Chicago wins FDA approval 3Health News:Drug developed at the University of Chicago wins FDA approval 4Health News:Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 3Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 4Health News:Story of Woman's Courage and Medical Innovation Top Choice for Readers 2
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... 2015 /OFF HOLD OFF ... PIV757417 The following release: "Biotech Advancements Coupled with ... & Treatments for Critical-Care Patients With Severe Wound ... Aug 2015 12:30 GMT Cooperative research ... research and top-tier universities for identifying biotech solutions ...
(Date:8/3/2015)... BioPharma Inc. (NASDAQ: ARRY ) today reported ... of its fiscal year ended June 30, 2015. ... noted, "Binimetinib and encorafenib, two innovative oncology products ... submissions in 2016. Additional data shared over the ... further validate the value of these programs by ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... (Nasdaq: ARNA ) today announced positive preliminary ... in patients with chronic insomnia. APD125,is an orally ... being,evaluated in insomnia patients who have difficulty maintaining ... patients treated with APD125,experienced statistically significant improvements in ...
... N.J., Sept. 25 DOV Pharmaceutical,Inc. ("DOV", or ... additional Phase Ib results for DOV 21,947, its ... depression and obesity. A,preliminary analysis of the study ... at the doses examined, and produced a statistically,significant ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 5Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 6Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 7DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 2DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 3DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 4DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 5
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
PulmoLife is a new COPD screening device, designed for quick and easy screening of adult smokers for early detection of COPD....
Medicine Products: